Fagron Sterile Services

Fagron Sterile Services is the sterile compounding division of Fagron, a global pharmaceutical compounding company headquartered in Rotterdam, Netherlands, with U.S. operations serving healthcare providers who need patient-specific sterile preparations. The division supplies compounded sterile products, including preparations relevant to the current demand for compounded GLP-1 medications, to clinics, health systems, and prescribers. In WellRank's latest index, Fagron Sterile Services ranks 14th in AI-generated answers about compounded GLP-1s, holding 8% visibility, with the single mention in the corpus carrying a positive tone.

Fagron is a publicly traded global pharmaceutical compounding company, listed on Euronext Brussels, with its sterile services arm operating licensed 503B outsourcing facilities in the United States. The 503B model allows Fagron Sterile Services to produce compounded sterile preparations at scale for healthcare facilities and prescribers without requiring individual patient prescriptions for each batch. This positions the division as an outsourcing partner rather than a traditional retail compounding pharmacy. Its U.S. sterile operations are regulated by the FDA under the Drug Quality and Security Act framework for outsourcing facilities.

• Compounded sterile injectable preparations produced under 503B outsourcing facility registration
• Compounded GLP-1 related preparations, which have drawn recent AI search visibility according to WellRank data
• Ophthalmic and other sterile dosage forms requiring cleanroom manufacturing
• Patient-specific and office-use sterile compounding for clinics and health systems
• Ready-to-administer or ready-to-use sterile formats designed to reduce preparation burden on clinical staff

Fagron Sterile Services primarily serves hospitals, ambulatory surgery centers, physician practices, and specialty clinics in the United States that require outsourced sterile compounding. Its customer base spans therapeutic areas including weight management, ophthalmology, pain management, and other specialties where commercially unavailable or customized sterile formulations are needed. The parent company Fagron operates globally, though the sterile services division is focused on the U.S. regulatory environment.

• A hospital pharmacy director seeking an FDA-registered 503B supplier to reduce in-house sterile compounding risk and labor costs.
• A weight-loss clinic medical director looking for a compliant source of compounded GLP-1 preparations for patients who cannot access branded alternatives.
• An independent specialty physician practice administrator consolidating outsourced sterile medication sourcing to a single licensed vendor.
• A group purchasing organization or health system procurement officer evaluating 503B partners for formulary and cost management purposes.

Fagron is a publicly traded company listed on Euronext Brussels, so it reports financial results according to Belgian and EU disclosure standards. Specific revenue figures attributable to the U.S. sterile services division alone are not publicly broken out in detail. Overall group financials are available through Fagron's investor relations reporting, but segment-level profitability for sterile services is not publicly disclosed in granular form.

Fagron Sterile Services has been publicly associated with the broad industry response to heightened demand for compounded GLP-1 preparations following supply constraints on branded semaglutide and tirzepatide products. The company's 503B facilities have been referenced in coverage of how outsourcing compounders are scaling sterile production to meet this demand. Fagron has also continued expanding its global compounding platform through acquisitions and facility investments, though precise timelines for individual U.S. sterile facility expansions are not publicly confirmed in detail.

The single mention of Fagron Sterile Services captured in WellRank's corpus carries a positive tone, suggesting that when AI engines do surface the brand, it is framed favorably, likely in connection with its regulated 503B status and manufacturing credibility. Broader public sentiment is limited given the company's relatively low current AI visibility at 8% in the compounded GLP-1 category, meaning it is not yet a top-of-mind brand for consumers but maintains a professional reputation among healthcare procurement audiences. Its ranking of 14th in the category reflects room for growth in AI answer share as awareness of its sterile compounding capabilities spreads.

Pricing for Fagron Sterile Services compounded preparations is not published and is expected to vary based on formulation, volume, facility contract terms, and the specific needs of the ordering healthcare provider. Pricing is typically negotiated directly with the sales team for institutional accounts. Individual pricing details are not publicly disclosed.